Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft citation policy

Consultation on the policy governing how the Institute cites evidence. The draft requires that every citation resolve to a retrievable source, that an identifier the Institute does not hold be recorded as not held rather than reconstructed, and that a claim…

Document identifier
CEI-CP-012
Series
Public comment period
Version
1.0
Published
05 Oct 2024
Last reviewed
05 Oct 2024
Next review
05 Oct 2025
Identifier
10.71829/cei.cp.12
Certainty
Not rated
Cycle
2024 Q3
Window
24 Jul 2024 – 18 Sep 2024
Status
Closed
Submissions
9

§1Consultation and window

§1.1Window

Opened
24 July 2024
Closed
18 September 2024
Duration
56 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
9

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the prohibition on reconstructing an identifier workable, given that a reader may expect an identifier where the Institute has none?
  2. Should a citation to a regulatory assessment document be treated as equivalent to a citation to a peer-reviewed report, or recorded as a distinct class of source?
  3. Is the requirement that every superscript resolve to a numbered entry on the same page a useful constraint or a formatting preference?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. Regulatory assessment documents are now recorded as a distinct source class with their own annotation, and the prohibition on reconstructing an identifier was retained without qualification.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.